Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
Recruiting now
Conditions studied: Ulcerative Colitis (UC), Crohns Disease
In brief
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Key facts
- Study ID
- NCT07431983
- Run by
- Asian Institute of Gastroenterology, India
- People needed
- 200
- Starts
- 2026-03-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-05-12
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- AIG Hospitals — Hyderabad, Telangana, India (enrolling)
- AIG Hospitals — Hyderabad, Telangana, India (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.